ReviewViruses2023
Herpes Simplex Virus and Varicella Zoster Virus Infections in Cancer Patients.
Review in Viruses, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 44 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
44 citing papers in PubMed, 73 citations in OpenAlex.
- Therapeutic effects of acyclovir and acyclovir-clobetasol nanofibers vs. cream formulation for recurrent herpes labialis.BMC oral health · 2024Trial
- Screening and identification of B-cell epitopes on the gH protein of varicella-zoster virus.Archives of microbiology · 2026Article
- Stereotactic radiosurgery for post-herpetic trigeminal neuralgia: results of a case-control study.BMC neurology · 2026Article
- Reactivation and Management of Endogenous Latent Herpesviruses in the Spaceflight Environment.Current microbiology · 2026Review
- Severe Disseminated Varicella Zoster in an Immunocompetent Adolescent: A Case Report.Clinical medicine insights. Pediatrics · 2026Article
- U-shaped association between estimated glomerular filtration rate and mortality in HSV-positive adults: A retrospective cohort study.Medicine · 2026Article
- Varicella Zoster Virus Infection: Clinical Features, Molecular Pathogenesis, Treatment, and Prevention.MedComm · 2026Review
- Cancer viroimmunotherapy platforms based on varicella-zoster virus and cytomegalovirus.Molecular therapy : the journal of the American Society of Gene Therapy · 2026Review
- Nanomedicine in maternal viral infections: advancing prenatal therapies for fetal protection.Discover nano · 2026Review
- Article
- Breakthrough Varicella During Chemotherapy in Two Vaccinated Children With Acute Leukemia.Cureus · 2026Article
- Herpes Simplex Virus Infection With Multiple Cerebral Hemorrhages: A Case Report.Clinical case reports · 2026Article
- Disseminated herpes zoster in adults: a single-center retrospective study on clinical spectrum and risk factors for adverse outcomes.Frontiers in medicine · 2026Article
- Prevalence of CMV, EBV, HPV, and HSV among South Asian healthy population: A systematic review and meta-analysis.PLOS global public health · 2026Article
- Article
- Antiviral Activity of Plant-Based Preparations against SARS-CoV-2 and Herpes Simplex Virus Type 2 In Vitro: A Review of Experimental Findings.Bulletin of experimental biology and medicine · 2025Review
- Determinants of Hospital Length of Stay in Herpes Zoster Patients: A Four-Year Retrospective Study.Health science reports · 2025Article
- Oncovirus classification and insights into herpes simplex virus, Varicella-Zoster virus.Cancer cell international · 2025Article
- Article
- Disseminated Varicella-Zoster Virus Infection with Internal Organ Involvement: A Scoping Review of 156 Cases.Viruses · 2025Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors at 1 institution in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Herpes simplex virus (HSV) and varicella zoster virus (VZV) are alpha herpesviruses that establish life-long latent infection in neuronal ganglia after primary infection. Periodic reactivation of these viruses results in recurrent infections that can have significant impact on patients' quality of life. HSV commonly causes oral and genital mucocutaneous infections whereas VZV is responsible for varicella/chickenpox and herpes zoster/shingles, but cancer patients are at particularly higher risk of complications including disseminated and visceral infections due to impaired cell-mediated immunity. While diagnosis of more common HSV and/or VZV infections is frequently clinically based, immunocompromised hosts may have atypical skin presentation or visceral involvement. Thus, diagnostic confirmation using virus-specific tests such as polymerase chain reaction or immunohistochemical staining is crucial in some cases. Oral acyclovir, valacyclovir and famciclovir are usually used for mild to moderate infections and intravenous acyclovir is the drug of choice for severe or disseminated infections. Foscarnet can be used when acyclovir-resistance is confirmed or suspected. Pharmaceutical prophylaxis against HSV and/or VZV should be considered in high-risk cancers patients. Currently, there is no commercially available vaccine against HSV, but VZV vaccines are available to prevent varicella and zoster.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.